Product Revenue, Net

9 Months Ended

Sep. 30, 2022

Product Revenue, Net

Product Revenue, Net

4.           Product Revenue, Net

ARCALYST

Following the approval by the U.S. Food and Drug Administration (“FDA”) of ARCALYST on March 18, 2021, the Company began generating product revenue from sales of ARCALYST in April 2021.

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2022		2021		2022		2021
Product revenue, net	$	33,424	$	12,095	$	82,585	$	19,799

The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2022:

	Contractual		Government
	Adjustments		Rebates		Returns		Total
Balance at December 31, 2021	$	515	$	719	$	101	$	1,335
Current provisions relating to sales in the current year		4,993		3,011		227		8,231
Payments/returns relating to sales in the current year		(3,797)		(1,659)		—		(5,456)
Payments/returns relating to sales in the prior years		(295)		(535)		—		(830)
Balance at September 30, 2022	$	1,416	$	1,536	$	328	$	3,280

Total revenue-related reserves as of September 30, 2022 and December 31, 2021, included in our consolidated balance sheets, are summarized as follows:

	September 30,		December 31,
	2022		2021
Reduction of accounts receivable	$	(157)	$	(50)
Components of other current liabilities		3,437		1385
Total revenue-related reserves	$	3,280	$	1,335